Nano Holdings, Inc. (4571) Cash flow
Market cap
¥10.6B
P/E ratio
-10.2x
NANO MRNA develops RNA-based drug candidates including mRNA and siRNA therapies, then licenses them to pharmaceutical companies for late-stage development and commercialization.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | |
| Depreciation & amortization | 19 | 28 | 21 | 26 | 9 | 1 | 2 | 3 | 0 | 1 | 0 |
| Cash from operations | -1,121 | -1,971 | -2,526 | -4,928 | -2,037 | -1,139 | -1,247 | -1,753 | -1,087 | -585 | -402 |
| Capital expenditures | -160 | -77 | -176 | -60 | -5 | -0 | - | -6 | - | - | - |
| Cash from investing | -2,562 | 7,385 | -597 | 215 | -992 | -112 | -872 | -244 | 1,208 | 793 | 588 |
| Repurchases of common stock | - | - | -0 | - | - | - | - | - | - | - | - |
| Cash from financing | 505 | 3,101 | 88 | 24 | 3,385 | 2,162 | -11 | 1,146 | - | 4 | -569 |
| Free cash flow | - | - | - | - | |||||||
| FCF margin (%) | - | - | - | - |